Welcome
New Home-Mid Content
WELCOME
The King's Thrombosis Centre is a leading multidisciplinary clinical and research group dedicated to the diagnosis and treatment of hypercoagulable conditions.
We are a designated Haemophilia Centre and were the first National Venous Thromboembolism (VTE) Exemplar Centre, reflecting our national leadership in the prevention and treatment of VTE. Our clinical trials unit works in partnership with industry to develop new treatments for VTE prevention and treatment.
THE FIRST REGISTRY
With the next generation of oral anticoagulants entering clinical practice, the FIRST registry will provide an important data tool to increase knowledge and improve the quality of care of patients with VTE.
King's Thrombosis Centre COVID-19 Research
Clinicians and researchers in the King’s Thrombosis Centre are completing a number of research studies relating to the COVID-19 pandemic.
Click here to view the latest publications from our centre, relating to this.
Click here to view the BBC interview with Prof Roopen Arya on thrombosis in COVID-19.
VTE EXEMPLAR CENTRE NETWORK WEBSITE
After being hosted at the King's Thrombosis Centre website since its launch in 2007, the website is now managed as part of the National VTE prevention Programme at NHS England. Click here to access the site.
Latest News
-
Anticoagulation news items. Week commencing 27th July 2020
Mortality risk associated with venous thromboembolism: a systematic review and Bayesian meta-analysis The Lancet HaematologyIn review of 86 RCTs, 52 of them, with data from >70 000 patients, were positive,…
-
Anticoagulation news items. Week commencing 20th July 2020
DTB select: MHRA DOAC safety reminder Drug and Therapeutics BulletinIt is noted that there has been a considerable increase in use of DOACs and a move to switch to them…
-
Anticoagulation news items. Week commencing 13th July 2020
Pulmonary embolism in COVID-19 patients: a French multicentre cohort study European Heart JournalStudy (n=1,240) identified independent risk factors linked to occurrence of PE in COVID-19 patients, including clinical and biological…
